DIA: Driving Insights to Action
Science:Life Sciences
“The pandemic had a substantial impact on community understanding of clinical trials. Having said that, the sort of ambient level of community knowledge of clinical trials is still substantially lower than it needs to be,” explains Australian Clinical Trials Alliance Board Chair Steve Webb. “Community awareness of the difference between evaluation of experimental interventions, about which relatively little is known regarding safety and effectiveness, compared with comparative effectiveness research, is an important distinction often with limited understanding in the community, in government, and amongst policymakers.”
Master Protocol Efficiencies Speeding COVID-19 Treatments
Found in Translation: A Tumultuous Year in Review
Biosimilar Awareness, Access and Savings Continue to Grow
R2D2 Aligning Regulatory and HTA Review to Quicken Patient Access
Jump In, Be Brave, Have the Conversation – Reducing Health Disparities among Minority Patients
CTD Speeding Medicines Registration in East Africa
Biosimilar Savings and Their Price: BPCIA Turns Ten
Regulators Promote Reliance as 21st Century Best Practice
Regulatory and Clinical Science Align to Fight COVID-19
DIA Keynote Calls for Expanded COVID-19 Trial Parameters
Impact Philanthropy Accelerating Cures Within Reach
FDA Guidance: Flexibility But No Compromise on Patient Safety
Digital Tools Powering More and Safer Clinical Trials
Latin America's COVID-19 Regulatory Response
Partnerships Essential to SAHPRA Pandemic Response
EFPIA Shares Industry View of EMA Regulatory Framework
Time to Press the Pause Button on Speedy Drug Approvals?
Reach More Patients While Improving Data Quality?
ATMPs May Deliver on Promise of Individualized Medicine
Relevance Will Put Europe on Investment Fast Track
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Speaking of Psychology
Stuff To Blow Your Mind